Document ID: chunk:federal_register_of_legislation:F2024L01528:clause:1_1
Version: federal_register_of_legislation:F2024L01528
Segment Type: clause
Provision Reference: sch 1 cl 1
Character Range: 2197–2777

1  Schedule 1 (cell at item 73295, column 2)
Repeal the cell, substitute:

     Detection of germline BRCA1 or BRCA2 pathogenic or likely pathogenic gene variants, requested by a specialist or consultant physician, to determine eligibility for a relevant treatment under the Pharmaceutical Benefits Scheme (PBS), in a patient with:

       (a) advanced (FIGO III‑IV) high‑grade serous or high‑grade epithelial ovarian, fallopian tube or primary peritoneal cancer for whom testing of tumour tissue is not feasible; or
       (b) breast cancer.

     Applicable once per lifetime